Several bispecific antibodies targeting AML antigens are being investigated in ongoing early-phase trials for relapsed/refractory AML, including agents directed against CD33, CD123, CLL-1, and FLT3 [9,120]. This evidence concerns the gene CD33 and acute myeloid leukemia.